本帖最后由 maicon08 于 2023-4-28 15:12 编辑
/ T! J9 ]/ E+ ^9 f7 d
; l. o8 M T9 r0 u' `2 R% h' ]! c一年一度的全球肿瘤界盛会-美国临床肿瘤学会（ASCO）年会将于当地时间6月2日-6月6日召开。ASCO年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议，致力于癌症的预防、治疗和改善患者管理，以展示肿瘤的基础研究和临床最新研究为特点，讨论当前国际先进的治疗方法。随着中国临床研究在肿瘤领域的快速成长，中国在世界肿瘤领域中也发挥着日益重要的作用。此次会议上，中国大陆研究Oral Abstract Session入选16项，另外Clinical Science Symposium和Rapid Abstract Session部分各有1项中国研究入选，共18项。
# m% v' \* O( i' q! g. J& g: B, E' W) i5 |8 o* [! z
https://www.163.com/dy/article/I3BTTPRD053438SI.html
! u- m5 w* ^4 d# ~( v) X+ J D- B* c- w
) O7 G+ Y4 U2 ]+ {# z1 M$ K7 C9 N在研疗法-免疫治疗
4 x. Y$ h+ K7 \) `! q* u" c( |Developmental Therapeutics—Immunotherapy
" ~+ b' O4 j0 T9 t! k! y " a$ T3 i9 P( E4 Z* A `# d
摘要号：2507 标题：Phase I study of the bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors. 报告人：丰恺超 单位：JFJ总医院第一医学中心
: j7 G! q. p% ?1 h$ }6 i" I! l
在研疗法-分子靶向药物和肿瘤生物学2 I5 n8 i! V1 s$ X' w! X
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology / Z, c. v* V' ]# |1 c5 M# d. e
摘要号：3001 标题：BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study. 报告人：张力 单位：中山大学肿瘤防治中心
7 J( {* C4 m, ?6 i3 ^& q
摘要号：3007 标题：A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors. 报告人：周清 单位：广东省人民医院
: u+ Q" O( p: J& c# o' m% k5 q
胃肠道肿瘤-结直肠癌和肛门癌
$ i( A5 B9 _( T5 M% p9 M% n, A Gastrointestinal Cancer—Colorectal and Anal 摘要号：3505 标题：Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial. 报告人：张剑威 单位：中山大学附属第六医院 8 E+ q. r( e( W/ @9 r) g( k) j! l
胃肠道肿瘤-胃食管癌、胰腺癌和肝胆癌 Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary - R" e7 c! M2 a
摘要号：4001 标题：Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial. 报告人：袁庶强 单位：中山大学肿瘤防治中心 U3 J% ?# I6 g' @8 ^0 x, N% T
妇科肿瘤 Gynecologic Cancer
) ~& q, B, [2 t. B2 V8 ^摘要号：5516 标题：Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy: A single-arm phase II trial. 报告人：田文娟 单位：复旦大学附属肿瘤医院
- ]# e6 V1 C3 C3 S( u
头颈肿瘤
' p& n* X# v$ l b9 a Head and Neck Cancer
& O3 t' F7 ~+ H! w1 X摘要号：6000 标题：Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial. 报告人：唐林泉 单位：中山大学肿瘤防治中心
9 B6 ~5 b$ m5 n) J1 v; f
摘要号：6001 标题：Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial. 报告人：陈明远 单位：中山大学肿瘤防治中心
: B4 V) r% P4 A/ {5 v7 k. ^
摘要号：LBA6002 标题：PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM). 报告人：马骏 单位：中山大学肿瘤防治中心 + ^; T% d3 j! r `
血液系统恶性肿瘤-淋巴瘤和慢性淋巴细胞白血病 Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
$ o4 a- E, K! y摘要号：7503 标题：Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: Primary analysis of the multinational pivotal study results (JACKPOT8). 报告人：蔡清清 单位：中山大学肿瘤防治中心
$ Y9 X/ a- p: a% Y# [1 X
血液系统恶性肿瘤-浆细胞疾病: f+ D; k0 P7 g: |7 Y( J
Hematologic Malignancies—Plasma Cell Dyscrasia - p _! Z1 W' T1 Y0 h
摘要号：8005 标题：Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM). 报告人：杜鹃 单位：上海长征医院
2 n# c7 M$ Y- F9 t1 z
肺癌-非小细胞局部-区域性/小细胞/其他胸部肿瘤
6 [5 X: F- L4 s7 w3 ]9 B+ O- l Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
, O W0 [) m$ N摘要号：8501 标题：Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study. 报告人：陆舜 单位：上海交通大学医学院附属胸科医院
( Z# A% g8 d8 y" f$ n" \; H
肺癌-转移性非小细胞肺癌0 V+ \0 O# t6 ?
Lung Cancer—Non-Small Cell Metastatic # ]0 i& t- a6 d. P8 f8 A+ S
摘要号：9001 标题：Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis. 报告人：吴一龙 单位：广东省人民医院 & C7 g9 C1 ~5 t6 s# K* Y
0 p. c! _. ^! S" r( p摘要号：9002 标题：Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results. 报告人：王孟昭 单位：北京协和医院
9 a% z7 r! R! k `6 g
摘要号：9003 标题：Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations. 报告人：邬麟 单位：湖南省肿瘤医院 2 k2 l8 e3 A# ?) A
黑色素瘤/皮肤癌
5 t! ]4 l9 M8 T Melanoma/Skin Cancers 摘要号：9508 标题：Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma. 报告人：郭军 单位：北京大学肿瘤医院
8 n6 a! q& l6 x$ f2 f: l8 m
快速摘要报告% p/ @ {" Z+ k; y( {0 ~
Rapid Abstract Session 摘要号：LBA1013 标题：TORCHLIGHT: a randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC). 报告人：江泽飞 单位：JFJ总医院第五医学中心 - w. Y/ Y4 q, p/ E! J
临床科学研讨会: f i- C( @; S5 v- n
Clinical Science Symposium 摘要号：11510 标题：The clinical value of tumor-informed minimal residual disease detection in sarcoma. 报告人：尹军强 单位：中山大学附属第一医院
! Y& T/ t. l7 ~# i5 X f9 y2 z, z
| 
发表于 2023-4-28 14:46:30
楼主
发表于 2023-4-28 14:53:34
发表于 2023-4-28 20:42:18
，中肿在保持鼻咽癌和食道癌这些优势的同时，头颈癌和血癌也逐渐发力了
